Ocular neovascularization is the abnormal growth of new blood vessels in parts of the eye where they do not belong. These fragile, poorly formed vessels leak fluid and blood, and left unchecked they can cause permanent vision loss through scarring, swelling, and retinal detachment. The process is driven largely by a single signaling molecule, vascular endothelial growth factor (VEGF), released when oxygen-starved tissue calls for more blood supply. The conditions that trigger it range from diabetes and age-related macular degeneration to premature birth and chemical burns, and the treatments now available have transformed what was once a near-certain path to blindness into a manageable, if demanding, chronic condition.
Why the Eye Grows Blood Vessels It Doesn’t Need
Healthy retinal and corneal tissue depends on a tightly regulated blood supply. The retina has its own layered network of tiny vessels, while the cornea is one of the few tissues in the body that is normally completely avascular, receiving oxygen directly from the air and the fluid behind it. When something disrupts the oxygen balance in either tissue, a molecular alarm goes off.
The central player is a transcription factor called HIF-1, made up of two subunits. Under normal oxygen conditions, one of those subunits (HIF-1α) is rapidly broken down, keeping HIF-1 activity low. When tissue becomes oxygen-deprived, HIF-1α accumulates and activates a cascade of genes, including the gene for VEGF. Research in ischemic retinas has shown that HIF-1α levels rise in close lockstep with VEGF expression, both in timing and location, consistent with HIF-1 being the upstream switch that turns on VEGF production in starving retinal tissue.1Investigative Ophthalmology and Visual Science. Hypoxia inducible factor-1α is increased in ischemic retina: Temporal and spatial correlation with VEGF expression When HIF-1α is experimentally blocked, VEGF expression drops and new vessel growth slows in a time-dependent fashion.2PubMed. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression
VEGF is not the only signal involved. A second pathway, centered on a molecule called angiopoietin-2 (Ang-2), works alongside VEGF and can independently destabilize blood vessels by causing the loss of pericytes, the support cells that wrap around capillaries and keep them intact. When Ang-2 and VEGF are both elevated, the combination promotes new vessel growth and leakage more aggressively than either signal alone.3PubMed Central. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases Understanding that there are at least two cooperating pathways matters for treatment, as blocking VEGF alone does not always fully control the disease.
The Major Conditions That Trigger It
Ocular neovascularization is not a standalone diagnosis. It is a complication that shows up across a wide range of eye diseases, each one starving tissue of oxygen in its own way.
Diabetic Retinopathy
Chronically elevated blood sugar damages the small vessels of the retina over years, eventually closing off capillaries and creating patches of tissue that receive no blood flow at all, called nonperfusion areas. High VEGF concentrations in the vitreous fluid drive further ischemia and the sprouting of new, abnormal vessels on the retinal surface.4PubMed Central. Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy This stage, called proliferative diabetic retinopathy, is one of the leading causes of blindness worldwide.
Age-Related Macular Degeneration
In the “wet” form of AMD, abnormal vessels grow from the choroid layer underneath the retina and break through toward the macula, the area responsible for sharp central vision. This choroidal neovascularization leads to fluid accumulation and eventually detachment of the retinal pigmented epithelium, the support layer behind the retina.5PubMed Central. Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction The process can destroy central vision within weeks if untreated.
Retinal Vein Occlusion
When a clot blocks a retinal vein, blood backs up, capillary pressure rises, and fluid leaks into surrounding tissue. Vision loss from central retinal vein occlusion most commonly comes from macular edema, the swelling of the central retina, but the resulting ischemia can also trigger neovascularization if enough retinal tissue is oxygen-deprived.6PubMed Central. Management of macular edema due to central retinal vein occlusion – The role of aflibercept
Retinopathy of Prematurity
Premature infants have incompletely developed retinal vasculature at birth. The disease follows a two-phase pattern: first the immature vessels degenerate, then, in response to the resulting oxygen deficit, abnormal new vessels proliferate. In severe cases, these vessels can cause tractional retinal detachment and permanent visual loss.7Survey of Ophthalmology. Retinopathy of prematurity: A review of pathophysiology and signaling pathways
Corneal Neovascularization
The cornea maintains its transparency partly by being vessel-free. A delicate balance of pro-angiogenic and anti-angiogenic signals keeps it that way. Infections, chemical burns, trauma, prolonged contact lens wear, and certain immune disorders can tip the balance toward vessel growth.8PubMed. Limbal stem cell deficiency and corneal neovascularization When the limbal stem cells at the edge of the cornea are severely damaged, the resulting corneal neovascularization tends to persist long after the initial injury and will not resolve without transplantation of those stem cells.9Progress in Retinal and Eye Research. Regulation of corneal angiogenesis in limbal stem cell deficiency
Systemic Risk Factors Beyond the Eye
The conditions above are the direct triggers, but the likelihood of developing neovascularization is influenced by your broader cardiovascular and metabolic health. A large study found that a history of cardiovascular disease was associated with more than a sevenfold increased odds of developing the wet form of AMD. Smoking roughly quadrupled the odds, as did being in the highest range for body mass index or serum cholesterol. Stage 2 hypertension tripled the odds.10Ophthalmology. Cardiovascular Disease and Hypertension Are Strong Risk Factors for Choroidal Neovascularization These are strikingly large associations, and they underscore that ocular neovascularization is not purely an “eye problem.” The same vascular damage that leads to heart attacks and strokes predisposes the eye’s delicate vessels to failure.
Kidney disease requiring dialysis adds its own risk. Hemodialysis sessions can temporarily drop blood pressure, reducing blood flow to the retina, and the rise in eye pressure during dialysis may compress retinal blood vessels further. Repeated episodes of this hemodynamic stress may push ischemic retinal tissue past the threshold where neovascularization begins.11PubMed Central. Risk factors for ocular neovascularization after central retinal artery occlusion
What You Actually Notice
One of the frustrating things about ocular neovascularization is how quietly it can progress. In its earliest stages, the new vessels themselves produce no pain and may cause no vision changes at all, especially when the growth is in the peripheral retina or beneath the macula where you would not notice it during daily activities. Many people discover they have proliferative diabetic retinopathy only during a routine dilated eye exam.
When symptoms do appear, they tend to reflect the complications of the new vessels rather than the vessels themselves:
- Blurred or distorted vision: Fluid leaking from abnormal choroidal vessels under the macula can make straight lines appear wavy, a phenomenon called metamorphopsia. It is common across different macular disorders and can be detected with tools as simple as an Amsler grid, a pattern of straight lines you view one eye at a time.12Karger. Metamorphopsia: An Overlooked Visual Symptom
- Sudden dark spots or floaters: When fragile new vessels in the retina bleed into the vitreous cavity, you may see a shower of dark spots or a curtain-like shadow.
- Painless central vision loss: In wet AMD, the damage to the macula can cause a dark or blank area in the center of your visual field, often noticed first while reading or recognizing faces.
- Eye pain with high pressure: If neovascularization extends to the iris and drainage angle of the eye, it can obstruct the outflow of fluid and cause a rapid rise in eye pressure, producing pain, redness, and nausea.
Dangerous Complications
The new vessels are structurally weak and tend to bleed, leak, and scar. Two complications deserve particular attention because they can cause irreversible damage quickly.
Neovascular glaucoma develops when new vessels and the fibrous membrane they carry spread across the iris and into the angle where fluid drains from the front of the eye. That membrane blocks the outflow of aqueous humor, causing eye pressure to spike.13PubMed Central. A review of neovascular glaucoma. Etiopathogenesis and treatment Neovascular glaucoma is one of the most difficult forms of glaucoma to manage and can lead to a painful, blind eye if not treated aggressively.
Tractional retinal detachment occurs when the fibrovascular tissue that accompanies new retinal vessels contracts and physically pulls the retina away from the wall of the eye. In proliferative diabetic retinopathy, this progression from neovascularization to vitreous hemorrhage and then to traction is a major contributor to severe vision loss.14PubMed Central. Tractional Retinal Detachment in Eyes with Vitreous Hemorrhage and Proliferative Diabetic Retinopathy and Posterior Vitreous Detachment in Fellow Eye Surgical repair with vitrectomy is possible, but outcomes are better the earlier the detachment is caught.
How Doctors Find and Monitor It
The traditional method for visualizing abnormal vessels is fluorescein angiography, where a dye is injected into a vein in the arm and photographs are taken as it circulates through the retinal vasculature. Leaking or abnormal vessels light up clearly. This remains a standard diagnostic tool, but it requires a needle stick, takes time, and occasionally causes allergic reactions.
A newer imaging approach, OCT angiography, generates detailed maps of retinal and choroidal blood flow without any dye injection. It works by detecting the movement of red blood cells through vessels in rapid, repeated scans. Studies have shown it can visualize blood flow within choroidal neovascular membranes even during remission phases of AMD, when the vessels appear quiet on standard imaging.15PubMed. Optical Coherence Tomography Angiography Reveals Blood Flow in Choroidal Neovascular Membrane in Remission Phase of Neovascular Age-Related Macular Degeneration It can also detect early forms of retinal neovascularization that might be missed otherwise.16PubMed Central. En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation)
OCT angiography is also useful for monitoring treatment response. After anti-VEGF injections, quantitative measurements of the abnormal vessel network show a rapid shutdown of blood flow during the first two weeks, followed by gradual reappearance of vessel channels by about week four, with fluid starting to re-accumulate around week six.17PubMed Central. OCT Angiography of Time Course of Choroidal Neovascularization in Response to Anti-angiogenic Treatment Patterns like these help clinicians decide when the next injection is needed.
Anti-VEGF Injections
The introduction of anti-VEGF drugs fundamentally changed the prognosis for most forms of ocular neovascularization.18PubMed Central. A brief history of anti-VEGF for the treatment of ocular angiogenesis These drugs are injected directly into the vitreous cavity of the eye, where they bind to VEGF and prevent it from activating the receptors on blood vessel cells. The result is regression of the abnormal vessels, reduced leakage, and in many patients, improved or stabilized vision.
Several anti-VEGF agents are in wide use: ranibizumab, aflibercept, and bevacizumab (used off-label) all target VEGF-A specifically. In retinopathy of prematurity, intravitreal anti-VEGF has been shown to cause involution of neovascularization and allow more normal vessel growth into previously avascular retina.19Journal of American Association for Pediatric Ophthalmology and Strabismus. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy For central retinal vein occlusion, intravitreal VEGF inhibition has become the most common therapy for the macular edema that causes vision loss.6PubMed Central. Management of macular edema due to central retinal vein occlusion – The role of aflibercept
The catch is that these drugs wear off. Most patients need repeated injections, often monthly or every two months, for years. Nearly half of patients with wet AMD report receiving nine or more injections per year.20PubMed Central. Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway That treatment burden is substantial and extends well beyond the injection itself.
The Weight of Ongoing Treatment
Getting a needle in your eye every few weeks sounds alarming, and even patients who have been through it dozens of times report significant anxiety. In a Norwegian survey of patients receiving anti-VEGF for wet AMD, about a quarter reported being anxious starting the day before treatment, and roughly one in ten described anxiety lasting a week or more before each appointment. About a third felt stressed in the week leading up to treatment, and about one in six had trouble sleeping.20PubMed Central. Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
The logistical burden is just as real. Many patients with advanced macular disease cannot drive themselves. Nearly four in ten needed a caregiver to accompany them to every appointment, creating a ripple effect on family members’ work schedules and daily lives. Financial costs, transportation difficulties, and the sheer time consumed by frequent clinic visits all weigh on patients and their families.21PubMed. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration This is part of why researchers are actively looking for treatments that last longer or can be delivered once.
Laser Photocoagulation
Before anti-VEGF drugs arrived, pan-retinal photocoagulation (PRP) was the mainstay treatment for proliferative diabetic retinopathy and remains widely used today, sometimes alongside anti-VEGF injections. The procedure uses a laser to deliberately destroy patches of peripheral retina, reducing the total oxygen demand of the tissue and thereby lowering VEGF production. It is effective at causing regression of new vessels and reducing the risk of severe vision loss, but it comes with trade-offs: peripheral vision narrows, night vision worsens, and some patients experience a reduction in contrast sensitivity. PRP treats the oxygen imbalance at its source but sacrifices some healthy tissue to do so.
For corneal neovascularization, different laser approaches may be used to target the invading vessels directly, although the results are less reliable than in retinal disease. In severe cases of limbal stem cell deficiency, laser treatment alone cannot solve the problem; the underlying stem cell loss must be addressed through transplantation.22The Ocular Surface. Matrix Revolution: Molecular Mechanism for Inflammatory Corneal Neovascularization and Restoration of Corneal Avascularity by Epithelial stem Cell Transplantation
Dual-Pathway Drugs and Bispecific Antibodies
Because VEGF is not the only signal involved, a newer class of drug targets two pathways at once. Faricimab, approved in 2022, is a bispecific antibody that blocks both VEGF-A and Ang-2 in a single molecule.3PubMed Central. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases The rationale is that blocking Ang-2 stabilizes blood vessel walls and reduces inflammation in ways that VEGF inhibition alone does not address.
Animal studies comparing dual blockade to single-target treatment found that while anti-VEGF and anti-Ang-2 each reduced lesion area to a similar degree, only the combination treatment significantly reduced the leakage from those lesions.23Frontiers in Cellular Neuroscience. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion For patients, the practical appeal of faricimab is the possibility of longer intervals between injections, with some patients in clinical trials extending to four months between doses.
When Anti-VEGF Stops Working
Not every patient responds indefinitely to anti-VEGF therapy. Some experience a fading response over time, and the distinction between two types of treatment resistance matters clinically. Tachyphylaxis is a rapid loss of response that can develop when injections are given frequently over a short period. The drug simply stops working, but if treatment is paused for a while, the response can return. Tolerance, by contrast, is a slower erosion of effectiveness. The drug still works, but less well, and increasing the dose or shortening the interval between injections can partially restore the effect, whereas pausing treatment does not help.24British Journal of Ophthalmology. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
In practice, clinicians often try switching to a different anti-VEGF agent or moving to a dual-pathway drug like faricimab when a patient’s response diminishes. The presence of fibrosis, where scar tissue has replaced the leaky vessels, is a harder problem; once fibrosis sets in, the damage is largely irreversible regardless of how well the remaining active vessels are controlled.
Gene Therapy on the Horizon
The most ambitious approach to reducing the treatment burden is gene therapy designed to make the eye produce its own anti-VEGF protein continuously after a single injection. The idea is straightforward: use a harmless viral vector to deliver a gene encoding an anti-VEGF molecule into retinal cells, which then manufacture the drug internally for months or years.
A growing number of gene therapy candidates based on adeno-associated virus (AAV) vectors are in development for wet AMD, with most aiming to sustain intraocular anti-VEGF production and reduce or replace the need for repeated injections.25Gene Therapy. AAV-based gene therapies for neovascular AMD In mouse models of choroidal neovascularization, a single injection of an AAV vector carrying an anti-VEGF antibody gene produced a dose-dependent reduction in new vessel growth, with the highest doses nearly eliminating it and reducing retinal detachment by roughly 70 to 80 percent, an effect that held for at least a month.26PubMed Central. AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration A separate approach using an AAV vector to deliver a soluble form of a VEGF receptor achieved sustained expression for up to 17 months in monkeys and caused long-term regression of abnormal vessels in 85 percent of treated mouse eyes over eight months.27Molecular Therapy. Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and Monkeys
These are animal results, and the jump to human eyes brings questions about dosing, immune responses to the viral vector, and how long the effect truly lasts. Several clinical trials are underway. If they succeed, gene therapy could transform the treatment experience from dozens of injections over a lifetime to a single procedure, which would be a meaningful change not just medically but in quality of life for patients who currently structure their weeks around clinic appointments.
The Complement System and Vessel Clearance
Beyond VEGF and Ang-2, the immune system’s complement pathway plays an unexpected role in how the eye handles abnormal vessels. The complement system is best known for helping the body fight infections, but it also participates in clearing damaged tissue. Research using mice lacking a key complement protein found that without a functional alternative complement pathway, the number of abnormal retinal vessels increased. The mechanism appears to involve a complement inhibitor called Cd55. Under low-oxygen conditions that characterize the environment around new vessels, Cd55 expression drops specifically on those vessels, essentially stripping them of their immune protection and marking them for removal by the complement system. Established, healthy vessels retain their Cd55 expression and are left alone.28PubMed Central. The alternative complement pathway regulates pathological angiogenesis in the retina This finding suggests the body has a built-in surveillance mechanism for tagging and eliminating pathological new vessels, and that harnessing or enhancing this system could open yet another treatment avenue.